This can likely be attributed to the absence of tumour progression steps leading to metastasis in subcutaneous xenografts, and to possible differences in the desmoplastic reaction between the two models that affect the efficacy of anti‐MMP9 stromal targeting. The gene discussed is MMP9; the disease is neoplasm.